Rekah Pharmaceutical Industry Stock Fundamentals
| REKA Stock | ILA 1,392 9.00 0.64% |
Rekah Pharmaceutical Industry fundamentals help investors to digest information that contributes to Rekah Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Rekah Stock. The fundamental analysis module provides a way to measure Rekah Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rekah Pharmaceutical stock.
Rekah |
Rekah Pharmaceutical Industry Company Return On Equity Analysis
Rekah Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rekah Pharmaceutical Return On Equity | 0.0222 |
Most of Rekah Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rekah Pharmaceutical Industry has a Return On Equity of 0.0222. This is 100.09% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all Israel stocks is 107.16% lower than that of the firm.
Rekah Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rekah Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Rekah Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rekah Pharmaceutical competition to find correlations between indicators driving Rekah Pharmaceutical's intrinsic value. More Info.Rekah Pharmaceutical Industry is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.94 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Rekah Pharmaceutical Industry is roughly 1.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rekah Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rekah Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rekah Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rekah Pharmaceutical's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rekah Pharmaceutical could also be used in its relative valuation, which is a method of valuing Rekah Pharmaceutical by comparing valuation metrics of similar companies.Rekah Pharmaceutical is currently under evaluation in return on equity category among its peers.
Rekah Fundamentals
| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 316.92 M | |||
| Shares Outstanding | 11.41 M | |||
| Shares Owned By Insiders | 37.27 % | |||
| Shares Owned By Institutions | 42.66 % | |||
| Price To Book | 1.11 X | |||
| Price To Sales | 0.63 X | |||
| Revenue | 263.95 M | |||
| Gross Profit | 65.16 M | |||
| EBITDA | 36.2 M | |||
| Net Income | 6.62 M | |||
| Cash And Equivalents | 31.61 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 101.23 M | |||
| Debt To Equity | 1.01 % | |||
| Current Ratio | 1.99 X | |||
| Book Value Per Share | 14.39 X | |||
| Cash Flow From Operations | 21.17 M | |||
| Earnings Per Share | 0.32 X | |||
| Number Of Employees | 399 | |||
| Beta | 0.0605 | |||
| Market Capitalization | 193.93 M | |||
| Total Asset | 437.09 M | |||
| Retained Earnings | 49 M | |||
| Working Capital | 156 M | |||
| Current Asset | 246 M | |||
| Current Liabilities | 90 M | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 437.09 M | |||
| Last Dividend Paid | 0.87 |
About Rekah Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rekah Pharmaceutical Industry's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rekah Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.